To assess the stability of IL‐38 concentrations in COVID‐19 patients during hospitalization, plasma IL‐38 concentrations were measured at multiple timepoints in the discovery cohort up to 32 days after admission. This evidence concerns the gene IL1F10 and COVID-19.